angela

Long-acting lenacapavir acts as an effective pre-exposure prophylaxis in a 1 rectal SHIV challenge macaque model

Lenacapavir / By

Pre-exposure prophylaxis (PrEP) using long-acting antiretroviral medications is a promising new HIV preventive method to daily oral regimens. A first-in-class long-acting capsid inhibitor called lenacapavir (LEN) has been licensed for the treatment of HIV-1 infection. In this study, the authors used a single high-dose simian-human immunodeficiency virus (SHIV) rectal challenge macaque 39 paradigms to evaluate […]

Long-acting lenacapavir acts as an effective pre-exposure prophylaxis in a 1 rectal SHIV challenge macaque model Read More »

Broadly neutralizing antibodies and long-acting antiretroviral drugs as treatments for HIV

Lenacapavir / By

Incorporating LA ARVs and bNAbs into regimens has proven to be a challenging task. For the dosage schedules of the two medicines to work together, identical half-lives are required. Additionally, bNAb susceptibility testing is required to ensure that the bNAb is active in order to protect against the possibility of developing resistance to the LA

Broadly neutralizing antibodies and long-acting antiretroviral drugs as treatments for HIV Read More »

High Acceptability and Perceived Feasibility of Long-Acting Injectable Antiretroviral Treatment Among People Living with HIV Who Are Viremic and Health Workers in Uganda

Cabenuva / By

The HIV treatment approach known as long-acting injectable antiretroviral therapy (LAI ART), which includes a bimonthly injection of cabotegravir/rilpivirine, appears promising. People who are hesitant to start LAI ART or who adhere to it poorly and who are not virally suppressed may gain the most from it. However, the acceptability and viability of LAI ART

High Acceptability and Perceived Feasibility of Long-Acting Injectable Antiretroviral Treatment Among People Living with HIV Who Are Viremic and Health Workers in Uganda Read More »

Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study

Cabenuva / By

A full, long-acting (LA) regimen for maintaining HIV-1 virologic suppression consists of cabotegravir (CAB) and rilpivirine (RPV), administered intramuscularly monthly or every two months. In this report, the authors provide the findings from week 152 of the ATLAS-2M antiretroviral treatment research.

Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study Read More »

Efficacy and safety of long-acting cabotegravir versus oral tenofovir disoproxil fumarate-emtricitabine as HIV pre-exposure prophylaxis: A systematic review and meta-analysis

Apretude / By

WHO guidelines recommend daily oral tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) for pre-exposure prophylaxis (PrEP) of HIV in people at high risk of HIV infection. However, due to social, psychological and other reasons, the compliance with daily oral TDF-FTC in real life is low. Long-acting cabotegravir is currently the only long-acting drug approved by

Efficacy and safety of long-acting cabotegravir versus oral tenofovir disoproxil fumarate-emtricitabine as HIV pre-exposure prophylaxis: A systematic review and meta-analysis Read More »

Long-acting antiretrovirals and HIV treatment adherence

Cabenuva / By

Long-acting cabotegravir with rilpivirine ART has reduced the required dosing frequency from once daily to once every month or every two months injections. This new era of long-acting ART, which includes other antiretrovirals and formulations in various stages of clinical development, holds tremendous promise to change the standard of HIV treatment.

Long-acting antiretrovirals and HIV treatment adherence Read More »

Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition

Apretude / By

CAB-LA is highly efficacious for HIV prevention with few safety concerns. CAB-LA may lead to an increased risk of INSTI resistance among those who have acute HIV infection at initiation or become infected while taking CAB-LA. However, results are limited to controlled studies; more research is needed on real-world implementation.

Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition Read More »

Factors Associated with Health Care Providers’ Preference for Forgoing an Oral Lead-In Phase When Initiating Long-Acting Injectable Cabotegravir and Rilpivirine in the SOLAR Clinical Trial

Cabenuva / By

Cabotegravir and rilpivirine long-acting (LA) antiretroviral therapy (ART) demonstrated similar safety and efficacy in maintaining viral suppression among participants switching from daily oral to LA ART in the Extension Phase of the FLAIR trial. The Phase IIIb SOLAR study comparing efficacy and safety of daily oral versus LA ART every 2 months allowed participants and

Factors Associated with Health Care Providers’ Preference for Forgoing an Oral Lead-In Phase When Initiating Long-Acting Injectable Cabotegravir and Rilpivirine in the SOLAR Clinical Trial Read More »

Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries

Cabenuva / By

Baseline rilpivirine drug resistance mutations (DRMs) are a risk factor for virological failure in patients treated with long-acting cabotegravir and rilpivirine (CAB/RPV LA). We investigated rilpivirine cross-resistance in treatment-naive and experienced patients in South Africa. One in 10 treatment-naive patients and 74.5% of patients failing treatment presented with rilpivirine DRMs.

Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries Read More »

Scroll to Top